A new machine learning approach classifies a common type of brain tumour into low or high grades with […]

The move is Huntsworth’s first acquisition under the ownership of Clayton, Dubilier & Rice

AbbVie will pay Genmab $750 million upfront, and potentially up to $3.15 billion in additional development, regulatory and […]

The company aims to target cancer with new drugs that take advantage of protein degradation

Evox’ technology modifies exosomes to deliver drugs to areas currently inaccessible

The drug did not significantly improve overall survival or progression free survival in the first-line setting

Updated Date: Thu, 04 Jun 2020 00:00:00 EDT

Updated Date: Thu, 04 Jun 2020 00:00:00 EDT

Updated Date: Thu, 04 Jun 2020 00:00:00 EDT

Updated Date: Thu, 04 Jun 2020 00:00:00 EDT